Last reviewed 2026-04-19 · How we verify

ACTINOQUINOL

Phase 2 active Small molecule

ACTINOQUINOL is a actinoquinol drug. It is currently in Phase 2 development.

Actinoquinol works by interacting with a specific molecular target, but its exact mechanism is currently unknown.

Actinoquinol is a small molecule drug in the actinoquinol class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile, pharmacokinetics, and generic availability. Further research is needed to fully understand this compound. Its development and ownership history are also not well-documented.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ACTINOQUINOL
Drug class	actinoquinol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and each lock has a unique key. Actinoquinol is like a key that fits into one of these locks, but we don't know which lock it is or how it works yet. This interaction can help regulate various cellular processes, but more research is needed to understand the details.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ACTINOQUINOL CI brief — competitive landscape report
ACTINOQUINOL updates RSS · CI watch RSS

Frequently asked questions about ACTINOQUINOL

What is ACTINOQUINOL?

ACTINOQUINOL is a actinoquinol drug.

How does ACTINOQUINOL work?

Actinoquinol works by interacting with a specific molecular target, but its exact mechanism is currently unknown.

What drug class is ACTINOQUINOL in?

ACTINOQUINOL belongs to the actinoquinol class. See all actinoquinol drugs at /class/actinoquinol.

What development phase is ACTINOQUINOL in?

ACTINOQUINOL is in Phase 2.

Drug class: All actinoquinol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing